COUGH MONITORING WITH STRADOS LABS

Cough and Lung Sound Measurement

The advanced, fit-for-purpose wearable for respiratory drug development and clinical trials

FDA 510(k) Class II Device | CE Mark | HIPAA Compliant

Technology Overview

The RESP Biosensor remotely captures 24-hour cough and lung sounds (wheeze, crackles, rhonchi) with exceptional clinical accuracy*
Reduces site and patient burden with its wireless, lightweight design and seamless data sync to the cloud
Collects objective, quantifiable data on respiratory symptoms from screening subjects to the research phases

*Results of Clinical Performance Testing in Chronic Lung Diseases, 2022 ATS Abstract

RESP Biosensor Measurements

Cough

Frequency and Severity

Lung Sounds

Wheeze, Rhonchi, Crackles

Additional Measures*

Respiratory rate, Activity level, Sleep/Wake

*Not yet cleared by the FDA

Strengthen Your Insight and Evidence Across Multiple Therapeutic Areas

The RESP Biosensor offers a patient-friendly, efficient approach to 24-hour ambulatory cough monitoring from screening subjects to the research phases. Strados Labs’ consensus labeling process ensures the highest level of accuracy in coughs counted.

Our technology also allows researchers to collect additional parameters beyond frequency that can reveal greater insights into patient quality of life, including cough intensity, spasms and bouts, sleep/wake*, body positioning* and activity level.*

Coughing and lung sounds such as crackles are strongly associated with IPF and ILD. The RESP Biosensor enables 24-hour monitoring of these symptoms to help researchers gain objective insight into treatment response in addition to subjective tools such as VAS and the Leicester Cough Questionnaire.

Cough is one of the primary symptoms of bronchitis with 24-hour cough monitoring frequently used to demonstrate treatment efficacy. The RESP Biosensor offers a more patient-friendly approach to cough monitoring for bronchitis with the ability to capture additional insights.

The RESP Biosensor allows researchers to objectively measure cough, lung sounds including wheeze and shortness of breath* in patients with COPD and Asthma, supplementing traditional measures such as spirometry and the COPD Assessment Test, Asthma Control Questionnaire, and the St. George’s Respiratory Questionnaire.

Infectious diseases such as COVID-19 and RSV impact the lungs and produce symptoms such as coughing, wheezing and shortness of breath. The RESP Biosensor can offer additional insight into how infectious disease therapies perform by measuring their impact on respiratory health.

Respiratory-related symptoms such as coughing, wheezing, and shortness of breath as well as crackles are common among Heart Failure patients. The RESP Biosensor offers an objective way for clinical trialists to objectively measure these symptoms.

*Measurement not FDA-cleared